Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rezolute, Inc. (RZLT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0700+0.1400 (+4.78%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close2.9300
Open2.8700
Bid0.5000 x 4000
Ask4.5700 x 4000
Day's Range2.8700 - 3.2889
52 Week Range2.2600 - 11.3100
Volume9,761
Avg. Volume62,385
Market Cap103.099M
Beta (5Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-3.0750
Earnings DateSep 13, 2022 - Sep 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RZLT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rezolute, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

    REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer. Dr. Roberts joined Rezolute in 2017 as Vice President of Clinical Developm

  • GlobeNewswire

    Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

    Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from Phase 1b multiple-ascending dose study of RZ402 enable Phase 2 proof-of-concept study initiation later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinic

  • GlobeNewswire

    Rezolute to Host Corporate Update Call on May 4, 2022

    Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ETREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management will be hosting a corporate update call. The call will highlight recent pipeline advancements and continued

Advertisement
Advertisement